StockWatch
·

ION EXCHANGE (INDIA) LTD.-$ Q2 FY27 Results

IONEXCHANGQ2 FY27 Results
Filing
Result:Poor· Market: Crashed#One-off hit

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue674.733.7%8.1%
Total Income682.533.4%8.8%
Expenditure790.9113.1%16.2%
PBT-108.381650.5%260.6%
Net Profit-82.762804.6%265.8%
OPM-12.56%17.09pp21.89pp
NPM-12.13%12.56pp18.80pp
EPS-6.842054.3%263.6%
View full financials

Infrastructure/EPC name swung to a net loss with revenue down 8.1% YoY and PBT turning sharply negative, a clear deterioration rather than a turnaround.

ION EXCHANGE (INDIA) · Q2 FY27 · THE VERDICT

Legacy Overrun Masks Order Strength—Recovery Hinges on Execution

Ion Exchange's ₹82.8 crore net loss stems from a ₹121.5 crore EBIT collapse in Treatment Solutions. But a resilient order book and 35% growth in Industrial Products suggest the quarter is more transitional than terminal.

12 Nov 2026 · 6 min read
Reported Revenue

₹674.7 Cr

-8.1% YoY

Reported PAT

-₹82.8 Cr

-265.8% YoY

Legacy cost impact

~₹121.5 Cr EBIT

Treatment Solutions overruns (≈90% of loss)

Adjusted operating trend

Mixed

Industrial +35%, Consumer -4.1 Cr EBIT

Where the profit came from

Ion Exchange's ₹82.8 crore net loss is not a story of operational collapse—it's a story of legacy contract cost overruns colliding with geopolitical headwinds. The Treatment Solutions segment, which was expected to be a stable cash generator, recorded a ₹121.5 crore EBIT loss in Q2 (vs. a ₹12.2 crore loss a year ago). Management attributes roughly 90% of the quarter's negative PAT to legacy project cost estimate revisions—meaning the organic business delivered a weaker but not disaster-level result. Strip that out and the company is managing through margin compression from input inflation and slower-than-expected ramp-up of its Roha specialty chemicals facility.

We have reached the bottom of the barrel as far as that is concerned. We have been talking for close to about 8 quarters in our calls.
Treatment Solutions Q2 EBIT Impact, ₹ Cr
-136.08-90.72-45.360-12.2Prior Year Loss-109.3Legacy cost overrun-121.5Q2 FY27 Loss
The ₹109 crore deterioration is almost entirely from revised cost estimates on legacy projects. Management says this provision is now complete.

Management's claims vs. what actually held up

Grading the on-call narrative

Legacy project cost overruns fully accounted for in Q2

Treatment Solutions EBIT loss ₹121.5 Cr reflects ~90% of negative PBT; management confident no further material adverse impact

Supported

Strong ₹296.9 Cr order book will drive H2 recovery

Order book is real but Treatment Solutions revenue halved YoY despite it; execution weak, geopolitical deferral risk material

Overstated

Roha plant at 25% utilization, ramp-up progressing

25% utilization achieved in Q2; facility commissioned Sept 2025; backward integration in final commissioning phase. Management acknowledged softer than expected.

Supported but softer than guidance

Consumer Products on track for FY27 breakeven

H1 EBIT loss -₹4.5 Cr despite 32% revenue growth; management says marginally below expectations but still projects end-FY27 breakeven

Overstated

Industrial Products momentum will continue

Q2 revenue ₹136 Cr (+35% YoY), H1 +25% YoY; EBIT at ₹86 Cr (vs ₹74 Cr); order inflow ₹81.3 Cr in Q2 driven by medium-sized and Hyundai deal

Supported

What shifted on this call

The quarter confirmed three things: (1) Industrial Products is the only segment firing on all cylinders — 35% YoY growth with strong order momentum (₹81.3 Cr inflow in Q2 alone, including the Hyundai Engineering & Construction deal worth USD 52.83 Cr). (2) Treatment Solutions is in triage mode — revenue collapsed 49% YoY to ₹149.8 Cr as legacy projects matured, GCC region dispatches deferred due to Middle East crisis, and accounting reversals hit. Management claims the worst is behind, but execution risk remains high. (3) Specialty Chemicals is ramping but dragging margins — Roha facility now operational at only 25% utilization (softer than expected), with facility costs and West Asia input inflation each dragging margins by roughly 7%. Consumer Products, despite 32% H1 revenue growth, remains unprofitable (-₹4.1 Cr EBIT in Q2, -₹4.5 Cr H1).

Geopolitical headwinds are material. West Asia crisis is raising specialty chemical input costs by 7–8% and deferring GCC region Treatment Solutions dispatches to H2. Management is working on pricing pass-through (domestic market showing better acceptance), but the international pass-through remains incomplete. Government receivables are also a drag — roughly 10% of total receivables are Jal Jeevan Mission contracts where fund flow is slower than expected, forcing management to calibrate dispatch in proportion to funds received.

The bull-bear ledger
  • Industrial Products +35% YoY, strong order inflow of ₹81.3 Cr in Q2

  • Order book ₹296.9 Cr + bid pipeline ₹937 Cr provide multi-quarter visibility

  • Hyundai Engineering & Construction contract (USD 52.83 Cr) signals new revenue tier

  • Specialty Chemicals revenue +17% YoY despite margin drag

  • Consumer Products revenue +32% YoY H1; franchise model showing early traction

  • ₹82.8 Cr loss driven by one-time legacy provisions (~90% of PAT); organic business weaker but not terminal

  • Legacy cost overruns suggest planning/estimation weakness, raising forward guidance credibility risk

  • Treatment Solutions revenue down 49% YoY despite ₹3,000 Cr order book — execution risk acute

  • Roha facility at softer 25% utilization; backward integration delays pushing margin recovery further out

  • Geopolitical deferral risk material (GCC dispatches delayed, input costs +7–8% unresolved)

  • Consumer Products breakeven target (FY27 end) remains aspirational; still loss-making despite 32% growth

  • Government receivable delays (~10% of total) creating cash flow headwind

Risks, ranked by how much they should concern a holder

Key risks and their materiality to shareholders

Execution on Treatment Solutions order book conversion (geopolitical deferral ongoing)

High

₹3,000 Cr order book is real, but Q2 revenue halved YoY despite it. Geopolitical deferral in GCC region means H2 ramp-up is not guaranteed. If execution slips, recovery narrative collapses.

Legacy contract cost estimation weakness (signal of forward-looking risk)

High

Management's cost overruns took 8 quarters to materialize fully. This reduces confidence in near-term guidance on margins, ramp-ups, and consumer breakeven targets. Signal: planning discipline is weak.

Roha facility ramp-up remains slow (25% utilization, facility cost drag)

High

Facility commissioned Sept 2025 but only at 25% utilization in Q2. Backward integration still in final commissioning. Margin recovery timeline extends further; near-term drag persists.

West Asia input cost inflation unresolved (pricing pass-through incomplete)

High

7–8% of Specialty Chemicals margin compression from West Asia crisis. Pricing pass-through in progress but international markets slower to accept. Further geopolitical escalation could widen margin pressure.

Consumer Products profitability timeline slipping (still loss-making despite growth)

Medium

32% revenue growth in H1 but -₹4.5 Cr EBIT loss. FY27 end breakeven target appears aspirational. If profitability lags, segment burns capital longer, pressuring consolidated returns.

Government receivables and Jal Jeevan Mission fund flow delays

Medium

~10% of receivables tied to govt. contracts with slower fund flow. Forcing dispatch calibration to available funds. Liquidity pressure if delays worsen.

How the street is positioned

The market confirmed the quarter's weakness and held skeptical. The stock fell 7.28% on day 1 (announcement day), extended losses to -10.34% by day 3, and recovered modestly to -2.58% by day 5. The move held lower — the market did not read the order book and Industrial strength as enough to offset legacy overruns and execution risk. That verdict aligns with the fundamental picture: a company in triage.

Valuation context: The stock trades at ₹322.5, a 58% discount to its all-time high of ₹768.4, and sits below all key moving averages (SMA20 ₹338.37, SMA50 ₹383.46, SMA200 ₹382.25). RSI at 37 is neutral—not oversold enough to signal a bounce, not rising enough to signal momentum. The stock is deeply beaten down but not yet attracting institutional buying.

Ownership data supports the cautious tone. FII holdings are stable at 4.86% (up a modest 23 bps QoQ from Q1 FY27), DII at 15.32% (up 52 bps), and promoter at 27.77% (down 11 bps). No institutional panic selling, but also no aggressive accumulation. Institutions are holding but watching—waiting for evidence of H2 execution before committing fresh capital. Promoter has trimmed marginally (11 bps), a sign of measured rebalancing rather than distress.

What to watch next

Three things that will resolve the debate by Q3
  • 1 · Treatment Solutions H2 execution ramp

    Does Hyundai contract delivery materialize as promised? Management would not quantify FY27 revenue from USD 52.83 Cr deal. GCC region dispatch cadence will reveal whether geopolitical deferral is truly temporary or structural.

  • 2 · Roha facility backward integration and margin recovery

    Completion of final commissioning phase targeted for FY27 end. Any delay pushes margin inflection further out. Pricing power and input cost pass-through gains are key — if margins remain compressed, the facility becomes a drag.

  • 3 · Consumer Products path to breakeven

    H1 loss of -₹4.5 Cr despite 32% growth raises questions about the breakeven target. Management says marginally below expectations, but the gap is material. Evidence of operating leverage (EBIT improvement per rupee of revenue) by H2 is the test.

This is steady-state recovery work, not a step-change. Ion Exchange has one solid business (Industrial Products, +35% YoY), one struggling business (Treatment Solutions, execution risk), and one growth story still proving its profitability thesis (Consumer Products). The order book is real, the geopolitical headwinds are real, and the cost inflation is real. None of these resolve immediately.

The stock is priced at 58% off its all-time high—a steep discount that reflects the market's skepticism of near-term recovery. That skepticism is justified until management demonstrates it can convert the order book into margin-accretive revenue despite geopolitical deferral and input inflation.

The single number to track from here is organic EBIT growth (adjusted for the legacy provision) in Q3. If H2 delivers improving EBIT despite flat or slightly declining revenue, the recovery narrative holds. If margins compress further or revenue remains depressed, the execution risk has materialized and the stock remains at risk of re-testing lower. The market is waiting for proof, not hope.

Informational and educational content only. Not investment advice.